乳腺肿瘤学项目-猫眼课题宝

乳腺肿瘤学项目

批准号：

10712665

负责人：

Laura J Van't Veer

金额：

$18.33万

依托单位：

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

依托单位国家：

美国

项目类别：

财政年份：

1999

资助国家：

美国

项目状态：

未结题

起止时间：

1999-08-05 至 2028-05-31

来源：

https://reporter.nih.gov/project-details/10712665

关键词：

Adverse effects Area Award Biology Breast Breast Cancer Risk Factor Breast Cancer Surveillance Consortium Breast Oncology Cancer Burden Cancer Center Support Grant Catchment Area Cells Classification Clinical Engineering Clinical Research Clinical Trials Communities Development Diagnosis Disease Drug Combinations Elements Ensure Ethnic Origin Extracellular Matrix Genetic Goals Healthcare Heterogeneity Individual Inflammation Intervention Laboratories Mammary Gland Parenchyma Mammographic screening Measures Methodology Methods Modeling Molecular Nature Neoadjuvant Therapy Neoplasm Metastasis Noninfiltrating Intraductal Carcinoma Oncogenic Outcome Participant Patient Outcomes Assessments Patient-Focused Outcomes Patients Pharmaceutical Preparations Phase Population Predisposition Prevention Prevention Measures Process Race Regimen Research Risk Risk Assessment Risk Reduction Safety Site Testing Therapeutic Time Tissues Training and Education Treatment outcome Tumor Tissue Woman Work breast lesion cancer risk cancer therapy cohort combinatorial community engagement demographics disorder risk drug development high risk improved improved outcome individualized medicine innovation insight malignant breast neoplasm member mortality neoplastic cell novel novel therapeutic intervention oncology program outcome disparities patient oriented personalized intervention personalized screening predicting response programs recruit response routine screening screening study population success therapy resistant trial design tumor tumor heterogeneity

项目摘要

项目成果

Laura J Van't Veer的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

Breast Oncology Program: Summary/Abstract The goal of the HDFCCC Breast Oncology (BR) Program is to reduce the risk of breast cancer development, progression, and mortality using innovative approaches and novel methodologies to reveal the molecular, cellular, and targetable networks that underlie susceptibility, heterogeneity, and outcome disparities. The translational nature of the program means that laboratory-based work in the program can be rapidly moved into clinical trials. The clinical research of the BR Program includes reducing overdiagnosis, over- and under- treatment, and the burden of cancer therapy through risk assessment to individualize screening and prevention measures, and through improved tumor classification to tailor treatment. BR research focuses on three areas: (1) understanding how tumor heterogeneity contributes to metastasis, dormancy, and therapeutic resistance; (2) developing new therapeutic strategies using innovation in trial design and drug development; and (3) better characterizing early breast lesions to improve screening, prevention, and health care value.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文